MS Misdiagnosis Rate Reaches 30% in Referral Centers Amid Diagnostic Criteria Updates

Christina Applegate publicly detailed her misdiagnosis on the MeSsy podcast, recounting a neurologist declaring she lacked MS only for symptoms to persist. The opinion writer from STAT News described a parallel 13-year odyssey ending in 2017 with an MS diagnosis after fibromyalgia and other labels failed to explain MRI lesions and progressive weakness. Both cases illustrate the McDonald criteria's reliance on clinical, imaging, and CSF findings rather than a single confirmatory test.

Observational data from MS referral centers indicate that 20-30% of patients initially labeled with MS are later found to have conditions such as neuromyelitis optica spectrum disorder, MOG antibody disease, or vitamin B12 deficiency. The 2017 and 2024 revisions to the McDonald criteria aimed to reduce false positives by requiring more specific dissemination in space and time plus exclusion of mimics, yet real-world application remains variable across non-specialist settings.

Absence of a validated blood or CSF biomarker forces MS to remain a diagnosis of exclusion, unlike Sjögren’s or rheumatoid arthritis where specific autoantibodies provide clarity. Ongoing studies in Lancet Neurology track novel antibody panels that reclassify 5-10% of presumed MS cases, suggesting current prevalence estimates may shift once these assays enter routine panels.

Future trials will test whether serum neurofilament light chain combined with advanced MRI protocols can achieve >85% specificity for MS versus mimics within a two-year diagnostic window. Until then, patients with atypical progression require prompt re-evaluation at tertiary centers.